Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC)

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2011
This article has no abstract
Epistemonikos ID: 3413b7d249099567b6a17143efc2d4e710a30927
First added on: Feb 04, 2025